Related Experiment Videos
[Delayed reaction in asthma].
1School of Medicine, Department of Pediatrics, San Francisco, CA 94143.
Allergie Et Immunologie
|November 1, 1990
Summary
Azelastine, like cromolyn, effectively inhibits both immediate and late phases of IgE-mediated hypersensitivity, including late-phase asthma. This dual action targets cellular activation and mediator release characteristic of the late phase.
Area of Science:
- Immunology
- Allergy Research
- Pharmacology
Background:
- Type 1 hypersensitivity involves immediate and late phases following allergen exposure.
- The late phase of asthma is characterized by cellular activation (lymphocytes, eosinophils) and distinct mediator release.
- Corticosteroids are known inhibitors of the late phase of allergic reactions.
Purpose of the Study:
- To investigate the inhibitory effects of Azelastine on both immediate and late phases of IgE-mediated hypersensitivity.
- To compare the mechanism of action of Azelastine with other known inhibitors like cromolyn and corticosteroids.
Main Methods:
- The study focuses on IgE-mediated type 1 hypersensitivity models.
- Analysis of cellular activation and mediator release during immediate and late phases.
- Pharmacological assessment of Azelastine's inhibitory effects.
Main Results:
- Azelastine demonstrates inhibition of both the immediate and late phases of hypersensitivity.
- The late phase involves specific cellular players and mediators distinct from the immediate phase.
- Azelastine's inhibitory profile extends to both phases, similar to cromolyn.
Conclusions:
- Azelastine is effective in inhibiting both immediate and late phases of IgE-mediated allergic responses.
- Its mechanism of action offers a dual inhibitory effect, targeting key components of both hypersensitivity phases.
- Azelastine presents a therapeutic option for conditions involving both immediate and late allergic reactions, such as asthma.